Enable Accessibility Enable Accessibility

Takeda to present 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting

banner

Takeda will present 14 abstracts in oncology and nine in hematology at the 2021 ASH Annual Meeting being held December 11-14, 2021. The highlights of data to be presented include:

Oncology

Abstract Number

Title

Session

Hodgkin Lymphoma

Abstract 1397

Use of Positron Emission Tomography in Patients With Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-center, Retrospective B-HOLISTIC Study

Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I

 

Poster Presentation,

December 11, 2021, 5:30 – 7:30 p.m. ET

 

Location: Hall B5

Chronic Myeloid Leukemia

Abstract 307

Post hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR-ABL1 level and Baseline Mutation Status in the OPTIC Trial

Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies

 

Oral Presentation, December 11, 2021, 4:00 – 5:30 p.m. ET

 

Location: B304-B305

Abstract 2550

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) From the PACE and OPTIC Trials

Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

 

Poster Presentation,

December 12, 2021, 6:00 – 8:00 p.m. ET

 

Location: Hall B5

Multiple Myeloma

Abstract 1666

Efficacy and safety of oral ixazomib (Ixa), intravenous (IV) daratumumab (Dara), and IV/oral dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: results of the second interim analysis (IA2) of a phase 2 study

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

 

Poster Presentation,

December 11, 2021, 5:30 – 7:30 p.m. ET

 

Location: Hall B5

Abstract 1656

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

 

Poster Presentation,

December 11, 2021, 5:30 – 7:30 p.m. ET

 

Location: Hall B5

Abstract 1678

Progression-free survival (PFS) according to the presence of adverse cytogenetic abnormalities in patients (pts) with multiple myeloma (MM) receiving ixazomib (ixa)-based vs placebo (pbo)-based therapy: A pooled analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 phase 3 studies

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

 

Poster Presentation,

December 11, 2021, 5:30 – 7:30 p.m. ET

 

Location: Hall B5

Abstract 2733

Late vs early response and depth of response are associated with improved outcomes in newly diagnosed multiple myeloma (NDMM) patients (pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) or placebo-lenalidomide-dexamethasone (pbo-Rd) in the phase 3 TOURMALINE-MM2 trial

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

 

Poster Presentation,

December 12, 2021, 6:00 – 8:00 p.m. ET

 

Location: Hall B5

Abstract 2701

The INSURE study (INSIGHT MM, UVEA-IXA, REMIX): a pooled analysis of relapsed/refractory multiple myeloma (RRMM) patients (pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice

Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological

 

Poster Presentation,

December 12, 2021, 6:00 – 8:00 p.m. ET

 

Location: Hall B5

Abstract 2726

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

 

Poster Presentation,

December 12, 2021, 6:00 – 8:00 p.m. ET

 

Location: Hall B5

Abstract 3045

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Outcomes Research—Lymphoid Malignancies: Poster II

 

Poster Presentation, December 12, 2021 6:00 - 8:00 p.m. ET

 

Location: Hall B5

Abstract 898

Modakafusp alfa (TAK-573), an immunocytokine, shows clinical activity in patients with relapsed/refractory multiple myeloma; updated results from a first-in-human phase 1 study

 

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

 

Oral Presentation, December 13, 2021, 6:15 – 7:45 p.m. ET

 

Location: A411-A412

 Higher-Risk Myelodysplastic Syndromes

Abstract 242

Pevonedistat (PEV) + Azacitidine (AZA) Versus

AZA Alone As First-Line Treatment for Patients

with Higher-Risk Myelodysplastic Syndromes

(MDS)/Chronic Myelomonocytic Leukemia

(CMML) or Acute Myeloid Leukemia (AML) with

20–30% Marrow Blasts: The Randomized Phase 3

Panther Trial (NCT03268954)

 

Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome

 

Oral Presentation, December 11, 2021, 2:00 – 3:30 p.m. ET

 

Location: B207-B208

Pipeline

Abstract 2742

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination With Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

 

Poster Presentation,

December 12, 2021, 6:00 – 8:00 p.m. ET

 

Location: Hall B5

Abstract 2488

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II

 

Poster Presentation,

December 12, 2021, 6:00 – 8:00 p.m. ET

 

Location: Hall B5

 

Hematology

Abstract 3184

Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia: Interim Results from an Open-Label Multicenter Clinical Trial

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III

 

Poster Presentation,

Monday, December 13, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

Abstract 2102

Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II

 

Poster Presentation,

Sunday, December 12, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

Abstract 3028

A Real-world Study of Pre-Post Annualized Bleed Rates and All Cause Costs Among Non-inhibitor Patients with Hemophilia A Switching from FVIII Prophylaxis to Emicizumab

Outcomes Research—Non-Malignant Conditions: Poster II

 

Poster Presentation,

Sunday, December 12, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

138 (Supplement 19)

Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and On-demand Treatment

Accepted for online publication only

Abstract 3118

Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics study

Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III

 

Poster Presentation,

Monday, December 13, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

Abstract 3185

Rurioctocog alfa pegol use in immune tolerance induction: Interim results from an open-label multicenter clinical trial in previously untreated patients with severe hemophilia A

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III

 

Poster Presentation,

Monday, December 13, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

Abstract 3187

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III

 

Poster Presentation,

Monday, December 13, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

Abstract 2104

Exposure-response relationship between von Willebrand factor (VWF) activity and bleeding events following prophylaxis with recombinant VWF (rVWF, vonicog alfa) in patients with severe von Willebrand disease (VWD)

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II

 

Poster Presentation,

Sunday, December 12, 2021: 6:00 PM-8:00 PM ET

 

Location: Hall B5

Abstract 2109

 

Recombinant porcine factor VIII in patients with congenital hemophilia a with inhibitors undergoing surgery: Phase 3, multicenter, single arm, open-label study

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II

Poster Presentation,
Sunday, December 12, 2021: 6:00 PM-8:00 PM ET

Location: Hall B5